Drugs / intravenous immune globulin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00642655 | Sep 2005 → May 2007 | — | Cedars-Sinai Medical Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | intravenous immune globulin | “Between September 2005 and May 2007, a total of 20 highly sensitized patients (with a mean [+/-SD] T-cell panel-reactive antibody level, determined by use of the...” PMID 18635429 ↗ Jul 2008 |
| Known as | IVIG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00642655 ↗ |
| Route | Intravenous | “IVIG 2gm/kg given intravenously on day#0 and day#30” NCT00642655 ↗ |